Quantum Biopharma Ltd.
QNTMDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
Firibastat
Hypertension
QGC001
Essential Hypertension
Ramipril
Myocardial Infarction
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Firibastat | Phase 3 | Hypertension | - | - |
QGC001 | Phase 2 | Essential Hypertension | - | - |
Ramipril | Phase 2 | Myocardial Infarction | - | - |
Frequently asked questions
What is in Quantum Biopharma Ltd.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Quantum Biopharma Ltd.'s (QNTM) pipeline across Phase 3, Phase 2. Its lead program is Firibastat (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Quantum Biopharma Ltd.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Quantum Biopharma Ltd. (QNTM) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track QNTM biotech catalysts?→
Add QNTM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Quantum Biopharma Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.